RSS Feed
- 3. Zanidatamab-hrii June 1, 2026Zanidatamab-hrii received Food and Drug Administration (FDA) approval for the treatment of adults with previously treated, unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive (immunohistochemistry [IHC] 3+) biliary tract cancer (BTC), as detected by an FDA-approved test, on November 20, 2024. This indication is approved under accelerated approval based on overall response rate […]
- 1. Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance June 1, 2026Boston Scientific received U.S. Food and Drug Administration (FDA) 510(k) clearance for the expanded indication of Rezūm™ Water Vapor Therapy, increasing the maximum prostate volume that can be treated with the device from 80 cm3 to 150 cm3 for patients with benign prostatic hyperplasia (BPH). Existing real-world and clinical trial data for Rezūm Therapy demonstrates […]
- 2. PAPZIMEOS June 1, 2026PAPZIMEOS was granted full approval by the US Food and Drug Administration (FDA) in August 2025, becoming the first and only approved therapy for the treatment of adults with RRP. PAPZIMEOS approval was supported by results from the pivotal Phase 1/2 study, which successfully met its primary safety and pre-specified primary eZicacy endpoints. Click here […]
- Why ACOs are shifting from claims to real-time network data June 1, 2026When it comes to patient data, ACOs are at a crossroads. Even as value-based care models increasingly move to reward proactive intervention, many are still operating with retrospective data.
- 0. Dyne Therapeutics June 1, 2026Dyne Therapeutics shared positive topline results from its Phase 1/2 trial of the investigational drug, zeleciment rostudirsen (also known as DYNE-251), in individuals with Duchenne muscular dystrophy amenable to exon 51 skipping. The study met its primary endpoint, demonstrating a statistically significant increase in dystrophin from baseline at 6 months. Furthermore, the treatment maintained a […]
- 6. NAMCP VBCC June 1, 2026NAMCP understands the changing landscape with regard to the delivery of healthcare moving from the traditional fee for service model to more of a focus on value based care and all of the complexities therein. The mission of the VBCC is to help payers and medical directors in their efforts to more effectively and efficiently […]
- 8. LivaNova June 1, 2026LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, has announced that the journal Brain Stimulation has published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study. The researchers evaluated the safety and efficacy of LivaNova's VNS Therapy™ System and its effectiveness on quality of life and daily function in […]
- Nearly 1.2 billion people worldwide are living with mental disorders. The number has been growing June 1, 2026Nearly 1.2 billion people worldwide had mental disorders in 2023, reflecting a 95.5% increase since 1990, a new study has found. The largest increases were in anxiety and depression, which were also the most common disorders in 2023.
- Primary care follow-up rare after mental health ER visits June 1, 2026When a patient with a mental health condition or a substance-use disorder seeks help in a hospital's emergency department, the ER staff's aim is to stabilize the patient for timely, comprehensive follow-up care by a primary-care clinician.
- Scientists create 'Trojan horse' weight loss drug that supercharges results June 1, 2026Researchers at Helmholtz Munich have developed a new drug strategy that could improve treatment for obesity and type 2 diabetes. Led by metabolism scientist Prof Timo D. Müller, the team created a hybrid molecule that uses the GLP-1/GIP signaling pathway as a kind of gateway into cells.
